MA51626A - Vecteurs d'adn à extrémité fermée pouvant être obtenus à partir d'une synthèse acellulaire et procédé d'obtention de vecteurs d'adnce - Google Patents

Vecteurs d'adn à extrémité fermée pouvant être obtenus à partir d'une synthèse acellulaire et procédé d'obtention de vecteurs d'adnce

Info

Publication number
MA51626A
MA51626A MA051626A MA51626A MA51626A MA 51626 A MA51626 A MA 51626A MA 051626 A MA051626 A MA 051626A MA 51626 A MA51626 A MA 51626A MA 51626 A MA51626 A MA 51626A
Authority
MA
Morocco
Prior art keywords
dna vectors
closed end
obtaining
available
acellular synthesis
Prior art date
Application number
MA051626A
Other languages
English (en)
Inventor
Ozan Alkan
Douglas Anthony Kerr
Robert Michael Kotin
Carolyn Pelletier
Matthew Stanton
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of MA51626A publication Critical patent/MA51626A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/103—Plasmid DNA for invertebrates
    • C12N2800/105—Plasmid DNA for invertebrates for insects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA051626A 2018-01-19 2019-01-18 Vecteurs d'adn à extrémité fermée pouvant être obtenus à partir d'une synthèse acellulaire et procédé d'obtention de vecteurs d'adnce MA51626A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862619392P 2018-01-19 2018-01-19

Publications (1)

Publication Number Publication Date
MA51626A true MA51626A (fr) 2020-11-25

Family

ID=67301565

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051626A MA51626A (fr) 2018-01-19 2019-01-18 Vecteurs d'adn à extrémité fermée pouvant être obtenus à partir d'une synthèse acellulaire et procédé d'obtention de vecteurs d'adnce

Country Status (14)

Country Link
US (1) US20210071197A1 (fr)
EP (1) EP3740571A4 (fr)
JP (2) JP2021511047A (fr)
KR (1) KR20200111726A (fr)
CN (1) CN111868242A (fr)
AU (1) AU2019210034A1 (fr)
BR (1) BR112020013319A2 (fr)
CA (1) CA3088984A1 (fr)
IL (1) IL275878A (fr)
MA (1) MA51626A (fr)
MX (1) MX2020005790A (fr)
PH (1) PH12020550878A1 (fr)
SG (1) SG11202005271TA (fr)
WO (1) WO2019143885A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006431WA (en) * 2018-02-14 2020-08-28 Generation Bio Co Non-viral dna vectors and uses thereof for antibody and fusion protein production
WO2020097417A1 (fr) * 2018-11-09 2020-05-14 Generation Bio Co. Adn à extrémité fermée modifié (cedna) comprenant des répétitions terminales inversées modifiées symétriques
GB201905651D0 (en) 2019-04-24 2019-06-05 Lightbio Ltd Nucleic acid constructs and methods for their manufacture
EP4189098A1 (fr) 2020-07-27 2023-06-07 Anjarium Biosciences AG Compositions de molécules d'adn, leurs procédés de fabrication et leurs procédés d'utilisation
GB202014772D0 (en) 2020-09-18 2020-11-04 Lightbio Ltd Nucleic acid construct
GB202014751D0 (en) 2020-09-18 2020-11-04 Lightbio Ltd Targeting vector
CN117043337A (zh) * 2021-01-25 2023-11-10 普利维尔治疗公司 基于aav的基因表达的调节
CN112980862A (zh) * 2021-02-25 2021-06-18 通用生物系统（安徽）有限公司 一种高纯度微环dna的制备方法
KR20240012370A (ko) 2021-04-20 2024-01-29 안자리움 바이오사이언시스 아게 아밀로-알파-1, 6-글루코시다제, 4-알파-글루카노트랜스퍼라제를 인코딩하는 dna 분자의 조성물, 이를 제조하는 방법 및 이를 사용하는 방법
WO2022232286A1 (fr) * 2021-04-27 2022-11-03 Generation Bio Co. Vecteurs d'adn non viraux exprimant des anticorps anti-coronavirus et leurs utilisations
JP2024515788A (ja) * 2021-04-27 2024-04-10 ジェネレーション バイオ カンパニー 治療抗体を発現する非ウイルスｄｎａベクター及びその使用
CA3218126A1 (fr) * 2021-05-07 2022-11-10 Matthew MANGANIELLO Compositions de vecteurs d'adn non viraux lyophilisees et leurs utilisations
WO2022236014A1 (fr) * 2021-05-07 2022-11-10 Generation Bio Co. Vecteurs d'adn non viraux pour l'administration de vaccins
WO2023122303A2 (fr) * 2021-12-23 2023-06-29 Generation Bio Co. Synthèse évolutive acellulaire et de haute pureté de vecteurs d'adn à extrémité fermée
WO2023135273A2 (fr) 2022-01-14 2023-07-20 Anjarium Biosciences Ag Compositions de molécules d'adn codant pour le facteur viii, leurs procédés de préparation et leurs méthodes d'utilisation
GB202204112D0 (en) 2022-03-23 2022-05-04 Lightbio Ltd Linear construct
EP4293101A1 (fr) 2022-06-14 2023-12-20 Asklepios Biopharmaceutical, Inc. Réacteur à température controlée et son procédé de fabrication
WO2024040222A1 (fr) 2022-08-19 2024-02-22 Generation Bio Co. Adn à extrémités fermées clivable (adnce) et ses procédés d'utilisation
WO2024119116A1 (fr) * 2022-12-01 2024-06-06 Generation Bio Co. Molécules d'adn simple brin synthétiques et leurs méthodes de production et d'utilisation
US11993783B1 (en) 2023-03-27 2024-05-28 Genecraft Inc. Nucleic acid molecule comprising asymmetrically modified ITR for improving expression rate of inserted gene, and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346415B1 (en) * 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
US8709778B2 (en) * 2008-10-28 2014-04-29 Xavier Danthinne Method of adenoviral vector synthesis
EP2500434A1 (fr) * 2011-03-12 2012-09-19 Association Institut de Myologie Vecteurs AAV sans capside, compositions et procédés pour la production des vecteurs et la thérapie génique
EP3517612A1 (fr) * 2013-03-15 2019-07-31 The University of North Carolina At Chapel Hill Répétitions terminales inversées de synthèse du virus adéno-associé
ES2898337T3 (es) * 2016-03-03 2022-03-07 Univ Massachusetts ADN dúplex lineal de extremos cerrados para la transferencia de genes no víricos
SG11202006431WA (en) * 2018-02-14 2020-08-28 Generation Bio Co Non-viral dna vectors and uses thereof for antibody and fusion protein production
SG11202107922QA (en) * 2019-01-24 2021-08-30 Generation Bio Co Closed-ended dna (cedna) and use in methods of reducing gene or nucleic acid therapy related immune response
CA3146966A1 (fr) * 2019-07-17 2021-01-21 Generation Bio Co. Compositions et production de vecteurs d'adn a extremites fermees nickeles
CA3147414A1 (fr) * 2019-07-17 2021-01-21 Generation Bio Co. Production synthetique de vecteurs de type adn viraux adeno-associes simple brin

Also Published As

Publication number Publication date
JP2023126487A (ja) 2023-09-07
BR112020013319A2 (pt) 2020-12-01
CN111868242A (zh) 2020-10-30
AU2019210034A1 (en) 2020-07-09
US20210071197A1 (en) 2021-03-11
EP3740571A1 (fr) 2020-11-25
PH12020550878A1 (en) 2021-04-05
IL275878A (en) 2020-08-31
EP3740571A4 (fr) 2021-12-08
JP2021511047A (ja) 2021-05-06
WO2019143885A1 (fr) 2019-07-25
MX2020005790A (es) 2020-10-28
SG11202005271TA (en) 2020-07-29
RU2020127017A (ru) 2022-02-21
KR20200111726A (ko) 2020-09-29
CA3088984A1 (fr) 2019-07-25

Similar Documents

Publication Publication Date Title
MA51626A (fr) Vecteurs d'adn à extrémité fermée pouvant être obtenus à partir d'une synthèse acellulaire et procédé d'obtention de vecteurs d'adnce
MA55560A (fr) Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer
MA51644A (fr) Méthodes d'évaluation de la capacité de transduction de vecteurs viraux
MX2022001410A (es) Composiciones y metodos de uso de 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamid a.
MA46699A (fr) Composés polymères libérant du sulfure d'hydrogène
MA55891A (fr) Synthèses en phase liquide convergente d'oligonucléotides
MA43848A (fr) Composés deutérés pour le traitement d'hémopathies malignes, compositions et procédés associés
MA55967A (fr) Procédés d'administration d'anticorps anti-cd38 pour traiter le myélome multiple
MA52934A (fr) Composés inhibiteurs de l'oga
MA50411A (fr) Ensemble pour la fixation d'unités remplaçables sur une paroi
GB202102399D0 (en) Methods of determining alzheimer's disease
UA45498S (uk) 1. інструмент «плавник» для проведення масажу
UA44452S (uk) Логотип «jul»
MA53258A (fr) Composés pour le traitement de la maladie d'alzheimer
UA44750S (uk) Логотип «зош»
UA46268S (uk) Логотип «тесro»
UA44218S (uk) Логотип «гетьман»
UA42663S (uk) Логотип «у самвела»
UA43633S (uk) Логотип «травник карпатський»
UA43135S (uk) Логотип «makasin»
UA42860S (uk) Логотип «goldens»
UA40210S (uk) Пристосування для шкіргалантерейних виробів «перетяжка 3802»
UA40209S (uk) Пристосування для шкіргалантерейних виробів «перетяжка 2146»
UA42270S (uk) Логотип «kvado»
UA42421S (uk) Логотип «шанtiliko»